Lakefront Biotherapeutics NV (LKFT) total assets
Lakefront Biotherapeutics NV (LKFT) had total assets of €3.41B at the end of fiscal 2025 (December 31, 2025). That is 17.6% lower than the €4.14B of fiscal 2024. Figures as of 18 Nov 2026, 09:40 UTC, from Yahoo Finance.
Key facts
- Total assets, fiscal 2025
- €3.41B
- Change on fiscal 2024
- −17.6%
- Highest on record
- €4.73Bfiscal 2022
- Lowest on record
- €3.41Bfiscal 2025
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in EUR. Figures, not advice.
Lakefront Biotherapeutics NV total assets, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was €4.73B in fiscal 2022 and the lowest €3.41B in fiscal 2025.
Total assets by fiscal year
Lakefront Biotherapeutics NV total assets, year by year
| Fiscal year | Total assets | Change | Year ended |
|---|---|---|---|
| 2025 | €3.41B | 17.6% down | |
| 2024 | €4.14B | 5.1% down | |
| 2023 | €4.36B | 8.0% down | |
| 2022 | €4.73B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.
How to read it
It measures the resources the business has put to work; assets that grow faster than profit mean each new unit of investment is earning less.
Lakefront Biotherapeutics NV, figure by figure
- Lakefront Biotherapeutics NV market cap
- Lakefront Biotherapeutics NV revenue
- Lakefront Biotherapeutics NV earnings
- Lakefront Biotherapeutics NV earnings per share (EPS)
- Lakefront Biotherapeutics NV P/E ratio
- Lakefront Biotherapeutics NV P/S ratio
- Lakefront Biotherapeutics NV P/B ratio
- Lakefront Biotherapeutics NV free cash flow
- Lakefront Biotherapeutics NV operating margin
- Lakefront Biotherapeutics NV dividend
- Lakefront Biotherapeutics NV shares outstanding
- Lakefront Biotherapeutics NV total debt
- Lakefront Biotherapeutics NV cash on hand
- Lakefront Biotherapeutics NV return on equity (ROE)
- Lakefront Biotherapeutics NV return on invested capital (ROIC)
Lakefront Biotherapeutics NV (LKFT) overview: price, valuation and scorecard
Lakefront Biotherapeutics NV total assets: questions and answers
How large are Lakefront Biotherapeutics NV's total assets?
Lakefront Biotherapeutics NV (LKFT) had total assets of €3.41B at the end of fiscal 2025 (December 31, 2025). That is 17.6% lower than the €4.14B of fiscal 2024.
What are the highest and lowest total assets figures on record for Lakefront Biotherapeutics NV?
Across the 4 fiscal years on record (2022–2025), the highest was €4.73B in fiscal 2022 and the lowest €3.41B in fiscal 2025.
How is Lakefront Biotherapeutics NV's total assets calculated?
Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest. For Lakefront Biotherapeutics NV it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total assets
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Lakefront Biotherapeutics NV (LKFT) total assets”, data as of 18 November 2026. https://funkfolio.com/stock/LKFT/total-assets
Underlying data: Yahoo Finance.